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Neuroprotection: The Way of 
Anti-Inflammatory Agents
Patrice Mendel Nzogang and Martial Boris Donkeng
Abstract
Neurons are basic structural and functional units of the nervous system with 
major function being that of integration and interpretation of neuronal input or 
information. The lifespan of a nerve cell generally last throughout the individual 
lifetime. However, some physiologic or pathologic processes may affect the neuron 
causing premature death of this cell or tissue. This premature neurological death 
caused by pathologic circumstances is what we call neurotoxicity. The biochemical 
mechanisms put forward to explain neurotoxicity are not fully known. Nonetheless, 
whatever the mechanism involved, the outcome usually results in apoptosis, pyro-
poptosis, or necrosis. Examples of these mechanisms include excitotoxicity, oxida-
tive stress, glial cell destruction, vascular interruptions, and inflammation. The idea 
about possibly protecting neurons against insults using pharmacologic means leads 
to the birth of the neuroprotection concept. This new concept has emerged based 
on ongoing research, suggesting it is possible through physical and pharmacological 
means to prevent or avoid neurotoxicity by the abovementioned mechanisms but 
with the exception of vascular interruption mechanisms. We will present in this 
chapter a synoptic view of the inflammatory mechanisms implicated in neurotoxic-
ity and bring out the possible implications in neuroprotection.
Keywords: neuroprotection, neurotoxicity, inflammation, inflammasome, NLRP3, 
metabolic syndrome
1. Introduction
Neurons represent the main component of the nervous system, and they are 
indispensable for integration and transcription of nerve impulses [1]. The central 
nervous system (CNS) is made up of about 100 billion neurons and approximately 
10–50 times more glial cells [1]. Unlike glial cells, which maintain the ability to 
undergo cell division even after adult age, neurons are no more capable of mitosis 
at the adult age. Nevertheless, they are supposed to live all the life of an individual 
[1]. Unluckily, there are some pathologic and physiologic circumstances during 
which we observe a premature neuronal death [2]. These include stroke, head 
trauma, neurodegenerative disease, psychiatric disease, multiple sclerosis, aging, 
etc. This premature neurological death caused by pathologic circumstances is what 
we call neurotoxicity. The biochemical mechanisms of neurotoxicity are not all 
described yet. Nevertheless, no matter the mechanism, the result will be either 
apoptosis, pyroptosis, or necrosis [3]. Reviewing the literature, we found several 
biochemical pathways described as being implicated in the process of neurotoxicity. 
These include excitotoxicity, oxidative stress, glial cell destruction, vascularization 
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interruption, and inflammation [3]. Being confronted with neurotoxicity, an idea 
emerged about possibly protecting neurons against insults using pharmacologic 
means. This was the birth of the neuroprotection concept.
The neuroprotection concept regroups all pharmacologic and/or physical 
resources capable of preventing or avoiding neurotoxicity by affecting one or 
more biochemical mechanisms of neurotoxicity [4, 5]. This definition excludes all 
therapeutics that lead to an improvement of the vascularization of the brain [4, 5]. 
The neuroprotection targets could therefore be avoidance of excitotoxicity, glial 
cell protection, oxidative stress reduction, and/or inhibition of inflammation. On 
the theoretical, logic and experimental fields, neuroprotection is evident; however, 
it remains a concept difficult to prove on the clinical field. Indeed, although many 
animal experimental researches on neuroprotection have been conclusive, this 
could not be confirmed in clinical trials. This could be explained by the difficulty to 
establish clinical criteria for the evaluation of neuroprotection in clinical researches. 
Despite this methodologic difficulty which tends to discredit the neuroprotection 
concept in clinical field, we propose to make an analysis of neuroprotection on 
the prism of inflammation. We will present a synoptic view of the inflammatory 
mechanisms implicated in neurotoxicity and bring out the possible implications in 
neuroprotection.
2.  Inflammatory reaction and particularities in the central nervous 
system
Inflammation is the first step in the defense mechanism of the organism by 
which the actions of different components of the nonspecific immunity are put 
together in order to fight against an exogenous or endogenous aggression [6]. By 
definition, inflammation is a local process which takes place in the connective tissue 
of the organ affected. Nevertheless, according to the amplitude and duration of 
the local inflammation, it can be secondarily generalized through production of a 
systemic response such as the synthesis of acute-phase reactants or the endocrine 
effect of cytokines [6, 7].
2.1 Inflammation response mechanism
The first step of an inflammation reaction is the adhesion of leukocytes on 
the endothelial membrane. This step takes place essentially in the postcapillary 
venule. Activated endothelial cells are required for this step as they need to express 
adhesion molecules on their surfaces. These molecules serve as receptor for their 
complementary adhesive molecules present on the surface membrane of circulat-
ing leukocytes. Leukocyte adhesion to the vascular endothelium occurs in two 
phases which implicate both adhesion molecules. The first phase is the leukocytes 
rolling on the vascular endothelium. It involves the E-selectin (CD62E) and the 
P-selectin (CD62P) expressed on the vascular endothelium transiently interacting 
the P-selectin glycoprotein ligand-1 (PSGL-1), E-selectin ligand-1 (ESL-1), and 
L-selectin (CD62L) which are ligands expressed on leukocytes’ surface. The second 
phase is the leukocyte-endothelium firm adhesion. It is realized by the interac-
tion between the vascular endothelium adhesion molecules named vascular cell 
adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) 
and leukocyte integrins known as VLA-4 and LFA-1 (Figure 1). The leukocyte 
adhesion is preceded by a certain number of steps which aid the adhesion phase. 
These steps are endothelial activation, induced by interleukin-1β (IL-1β) and tumor 
necrotic factor α (TNFα); the activated endothelium secretes some agents such as 
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platelet-activating factor (PAF), prostaglandin E2 (PGE2), and azote monoxide 
(NO) which lead to a vasodilatation with reduction of blood flow aiding leukocyte 
rolling. Interleukin-1β and TNFα are also responsible for the adhesion molecules 
expressed on the endothelial surface and the liberation of chemotactic agents.
The second step of inflammation is diapedesis; it follows the leukocyte adhesion 
and refers to the passage of leukocytes from blood circulation to the connective 
tissue where the inflammation process has begun. This leukocyte migration is done 
across the intercellular endothelial junctions and is affected by chemotactic peptide 
concentration gradient at the inflammatory focal point. At the inflammatory focal 
point, leukocytes become activated and start to secrete oxygen-reactive substances, 
pro-inflammatory cytokines, and lipid inflammatory mediators. They also excrete 
the contents of their granules. All these actions lead to a systemic inflammatory 
response by endocrine effects of pro-inflammatory cytokines and also cessation of 
the cause of the inflammation. However, in certain cases the amplification of the 
inflammation by pro-inflammatory cytokines is responsible of destruction of the 
tissue where it takes place [7]. The endocrine effects of pro-inflammatory cytokines 
are multiple; the principal effects are observed on the liver and the brain [8]. In the 
liver, they induce the synthesis of acute-phase proteins; on the brain, they result in 
fever, asthenia, anorexia, and somnolence (Figure 2).
2.2 Inflammatory cytokines
The term cytokine regroups the low-molecular-weight glycoproteins implicated 
in cellular communication. They are active in the control of proliferation, matura-
tion, and differentiation of hematopoietic cells and also in the regulation of inflam-
matory and immunologic responses. They exercise their regulatory activity through 
an autocrine, paracrine, juxtacrine, and endocrine mechanism via the membrane 
receptors present on focus cells. In the field of immunology, there exist two groups 
of cytokines: pro-inflammatory cytokines such as interleukins 1, 6, 8, and 18 (IL-1, 
IL-6, IL-8, IL-18), TNFα and anti-inflammatory cytokines such as interleukins 10, 
4, and 13 (IL-10, IL-4, IL-13) transforming growth factor β (TGFβ). The balance 
between pro-inflammatory and anti-inflammatory cytokines regulates the local 
intensity of an inflammatory reaction and its duration. Among pro-inflammatory 
cytokines, IL-1β and TNFα have the central role in the initiation and chronicity 
Figure 1. 
Mechanism of inflammation reaction.
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of inflammation. These cytokines are synthetized in an inactive precursor form: 
pro-IL-1β and pro-TNFα. Activation of pro-IL-1β is done by a cysteine/aspartate-
type membrane protease named caspase-1 or IL-1β converting enzyme (ICE). 
Concerning TNFα, its liberation and activation require an adamalysine family 
enzyme called TNFα- converting enzyme (TACE). Interleukin-1β and TNFα have a 
synergetic action at the inflammation focal point; they are implicated in the expres-
sion of cyclooxygenase 2 (COX2); production of PGE2, NO, and PAF; expression of 
adhesion molecules at the endothelium level membrane; production of other pro-
inflammatory cytokines; liberation of chemotactic peptides and metalloproteases; 
etc. The activities of these major pro-inflammatory cytokines are under the control 
of many natural inhibitors. These inhibitors can be classified regarding their mode 
of action into three categories:
• The pro-inflammatory cytokine receptor antagonists: they compete with pro-
inflammatory cytokines on their receptors.
• The pro-inflammatory cytokine soluble receptors: they inhibit pro-inflamma-
tory cytokine activities binding them; this family is represented by truncated 
receptors of IL-1β (IL-1 R1 and R2) and TNFα (TNF R55 and R75).
• The anti-inflammatory cytokines: they act by inhibition of pro-inflammatory 
cytokine biosynthesis; this family is represented by IL-4, IL-10, IL-11, IL-13, 
and TGFβ.
Chemokines constitute another group of pro-inflammatory cytokines; they have 
chemotactic properties for the leukocytes. They are produced by all leukocytes, 
platelet, and connective tissue cells following stimulation by bacterial or viral 
products, IL-1β, TNFα, fragment C5a of complement, and leukotriene. Chemokine 
release leads to the degranulation and activation of leukocytes which provoke a 
massive release in the inflammatory focal point of lysosomal enzymes, oxidant, and 
lipid mediators [7].
Figure 2. 
Role of sentinel cells in the inflammatory response (modified from [8]). Sentinel cells (macrophage in this 
case) detects in its environment a potential danger by the pattern recognition receptors (PRR). This recognition 
active the inflammation signalization ways with the liberation of pro-inflammatory cytokines. PRRs considered 
in this example are toll like receptor 4 (TLR4) which recognize the lipo-poly-saccharide (LPS) of Gram 
negative bacteria and RAGE which recognize the ends products of glycation (AGEs).
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2.3 Particularities of inflammation in the central nervous system
In the central nervous system (CNS), the same inflammatory mechanism 
previously described remains valid. However, because of the blood–brain barrier, 
the actors and kinetic of inflammation in the CNS are particular [9]. Furthermore, 
in the CNS, the immune reactions are molded by the presence of cellular and 
molecular factors slowing the immune response [9]. In the physiologic conditions, 
the blood–brain barrier is not permeable to blood constitutes including immune 
cells. This immune isolation of the CNS brings up the question about the actors 
implicated in an inflammatory reaction in this particular organ. Many studies prove 
that the microglial cells located in the periventricular spaces express the class II 
molecules of the major histocompatibility complex (class II MHC) and can play 
the role of macrophages in the initiation and amplification of inflammation [9, 10]. 
Hence, microglial cells can be activated in CNS by three ways: pathogen-associated 
molecular patterns (PAMPs), missing self, or danger-associated molecular patterns 
(DAMPs) [11, 12]. This microglial cell activation leads to phagocytosis, antigen 
presentation, and production of pro-inflammatory cytokines [13]. Furthermore, 
the active microglial cells express the co-stimulant molecules including CD45, B7–1, 
B7–2, LFA-1, CD40, ICAM-1, and VCAM-1 which increase the permeability of the 
blood–brain barrier resulting in the penetration of immune cells in the CNS [9, 13]. 
It is possible for the active T lymphocytes to cross the blood–brain barrier and pen-
etrate into the brain parenchyma [14]. If these infiltrated T lymphocytes recognize 
their specific antigen, they will produce pro-inflammatory cytokines that further 
increase the permeability of the blood–brain barrier [9]. However, this inflam-
matory activity caused by activated microglial cells or activated T lymphocyte in 
the CNS remains strongly modulated and inhibited by many cells and molecular 
immunosuppressing factors present in the CNS.
In the CNS, they are unappropriated conditions for the development and amplifi-
cation of an inflammatory reaction. Indeed, we observe in the CNS a reduction of the 
expression of class I and class II molecules of the major histocompatibility complex 
on the cells, a local production of anti-inflammatory cytokines and a continuous 
elimination, by apoptosis, of the active T lymphocytes that have crossed the blood–
brain barrier [9]. This apoptotic elimination of infiltrated T lymphocyte is the result 
of an interaction between receptors Fas/Apo-1 (CD95) on the active T lymphocytes 
and ligands FasL (CD95L) on the CNS cells [15, 16]. This “inflammo-resistance” 
state of the CNS is not necessarily an advantage. Indeed, low expression of class I 
molecules of the major histocompatibility complex on the CNS cells leads to two 
potential consequences. Firstly, it may be possible for the active immune cells if they 
cross the blood–brain barrier to attack the self CNS cells following the “missing self” 
principle [11]. Secondly, it may be difficult for active cytotoxic T lymphocyte when 
they cross the blood–brain barrier to destroy infected CNS cells in the case of CNS 
viral infection [17]. These consequences make the CNS particularly susceptible to 
persistent inflammatory states once the pathogen or other cause of inflammation has 
circumvented all the anti-inflammatory processes present in CNS [17]. Furthermore, 
even if apoptotic elimination of infiltrated active T lymphocytes leads to a modu-
lation of inflammation in the CNS, it also delays the elimination of the cause of 
inflammation and therefore prolongs the inflammatory state in the CNS. Apoptosis 
of infiltrated active T lymphocytes also leads to the release, in the CNS parenchyma, 
of anti-inflammatory cytokines notably IL-10 and TGFβ which inhibit the cytotoxic 
activity of active T lymphocytes and thus might perpetuate an eventual CNS viral 
infection [18, 19]. It appears that it is difficult for an inflammatory process to begin 
in the CNS, but if for one reason or the other an inflammatory process does begin in 
the CNS, it becomes very difficult to avert it completely and rapidly.
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3. Inflammasome molecular platform
3.1 Description of an inflammasome
Inflammation is amplified and maintained by the activities of pro-inflammatory 
cytokines principally IL-1β and IL-18. However, the previously described inflam-
matory mechanism leads to the formation of these cytokines in an inactive form. 
In this part, we focus on the analysis of the molecular platform implicated in the 
activation of these cytokines called inflammasome. An inflammasome is an innate 
immune complex that recognizes pathogen-associated molecular patterns (PAMPs) 
and danger-associated molecular patterns (DAMPs) and leads to the activation of 
an inflammatory caspase: caspase-1 [20]. It is a macromolecule complex formed by 
oligomerization of a specific type pattern recognition receptor, an adaptor protein 
and caspase-1. This association results from the interaction between homotypic 
domains [20]. Pattern recognition receptors (PRRs) implicated in the inflamma-
some’s structure are particular. Their activation leads specifically to the activation of 
caspase-1 rather than the activation of transcription factors such as nuclear factor 
kappa-B (NF-κB) or IFN regulatory factor 3/7 (IRF3/7) as well as protein synthesis 
[20]. Three receptors’ families are actually descripted as principal activators of the 
inflammasome: nucleotide-binding domain and leucine-rich repeats containing 
receptors (NLR), AIM2 {absent in melanoma 2}-like receptors (ALR), and RIG 
{retinoic acid inducible gene}-I-like receptor (RLR) [20]. The implication of the 
RLR in the activation of inflammasome is still debated.
Twenty-two NLR types have been identified in humans. They have a structural 
organization with a leucine-rich repeat (LRR) domain, which interacts with the 
ligand; a nucleotide-binding domain (NBD), which permits the ATP depending 
oligomerization of NLR into an hexameric form that activates the inflammasome; 
and an effector domain, which permits the transduction of signals (Figure 3) [21]. 
The effector domain is different for each NLR receptors and aids in their distinc-
tion. The NLRP have as effector domain the pyrin domain (PYD); the NLRC have as 
Figure 3. 
Inflammasome structure (modified from [20]) (A) structure of Inflammasome domains (B) NLRP3 
Inflammasome. *Apoptosis-associated speck-like protein containing a CARD plays the role of adaptor protein.
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effector domain the caspase activation and recruitment domain (CARD); and the 
NLRB or NAIP (NLR family apoptosis inhibitory protein) have as effector domain 
the baculoviral inhibitor of apoptosis protein repeat (BIR) [21]. AIM2-like receptors 
(ALR) are formed by four receptors: the AIM2, interferon-γ- inducible antigen 16 
(IFI16), myeloid cell nuclear differentiation antigen (MNDA), and interferon-
inducible protein X (IFIX). The end carboxyl extremity of these receptors is formed 
by an HIN200 domain which reacts with double-stranded DNA, and the end amino 
extremity is formed by a pyrin domain [20].
3.2 Activation of the inflammasome
Activation of inflammasome requires the interaction between its receptors 
and the specific ligands grouped in the name of pathogen-associated molecular 
patterns (PAMPs) and danger-associated molecular patterns (DAMPs) [11, 12]. 
A large number of inflammasome ligands have been identified; the major ones 
are presented in Table 1. Receptors implicated in the inflammasome structure are 
located on the intracellular site of cell membrane. This localization means that 
the inflammasome’s receptors are activated by ligands present on the inner aspect 
of the cell [20]. In other words, an inflammasome is activated in a cell only if the 
considered cell is infected, mutated, or damaged. The most studied inflammasome 
platform is the NLRP3 or cryopirine; its activation can be mediated by a double 
stimulus. The first is the stimulation of a toll-like receptor (TLR) which leads to 
the activation of the transcription pathway of pro-IL-1β that raises the transcrip-
tion of the genes of NLRP3 and its deubiquitination [22]. The second stimulus is 
Receptors Stimuli DAMPs/PAMPs
NLRP1 Anthrax toxin PAMP
Myramyl dipeptide of peptidoglycan bacterial wall PAMP
NLRP3 Extracellular ATP DAMP
Reactive oxygen species DAMP
Asbestos fiber DAMP
Potassium ions efflux DAMP
Urate crystal DAMP
Silica crystal DAMP
Aluminum salt DAMP
Cholesterol crystal DAMP
β-amyloid protein DAMP
Pore forming bacteria toxin PAMP
NLRP6 Unknown Unknown
NLRP7 Bacteria lipopeptide PAMP
NLRP12 Yersinia pestis unknown pattern PAMP
NLRC4 Flagellin PAMP
Type 3 and 4 secretion system PAMP
AIM2 Bacterial and viral DNA PAMP
IFI16 Viral nuclear DNA PAMP
Table 1. 
Major Inflammasome activators (modified from [20]).
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done directly on the NLRP3 through its receptors by a DAMP expressed by the cell 
secondary to the first stimulus and linked to a cell membrane damage, trouble of 
cell ionic or metabolic homeostasis, etc. Another activation mechanism of NLRP3 is 
described in Alzheimer’s disease and implicates the β-amyloid protein [23]. Beta-
amyloid proteins activate the inflammasome pathway in the microglial cells and 
thus provoke the liberation of IL-1β and its pyropoptosis which lead to neural cell 
death. Inflammasomes are also activated by reactive oxygen species resulting from 
mitochondrial malfunctioning or destruction [20].
Regardless of the inflammasome receptor activating stimulus, it causes a 
conformational modification of the receptor with liberation of the NBD domain. 
This liberation of the NBD domain permits the oligomerization of the inflamma-
some receptor into a hexamer or heptamer and recruitment of an adaptor protein 
by homotypic PYD-PYD interaction in the case of NLRP3. The recruited adaptor 
protein also recruits the procaspase-1 by homotypic CARD-CARD interaction. The 
obtained conformational two-by-two rapprochement of procaspase-1 leads to their 
autoproteolytic cleavage and their autoactivation [20]. On active form, caspase-1 
is a tetramer formed by two pairs P10 and P20 subunits. Active caspase-1 produces 
activation of IL-1β and IL-18 and the outbreak of pyropoptosis by induction of 
cell membrane pore formation, which leads to water influx into the cell, swelling, 
and then osmotic lysis. Interleukin-1β and IL-18 amplify inflammation reaction 
and activities of all types of lymphocyte. Pyropoptosis, defined as inflammatory 
programmed cell death, has been found in macrophages, dendritic cells, and 
neurons [24]. So, in the CNS, inflammation through inflammasome and caspase-1 
activation leads to pyroptosis of neurons and microglial cells that play the role of 
macrophages. This cellular death occurs indirectly in the case of microglial cell 
death or directly in the case of neuronal death resulting in significant neurotoxicity 
observed in many diseases.
4. Inflammation in neurotoxicity and neuroprotection
4.1 Inflammation in neurotoxicity
At the level of the central nervous system (CNS) as we have shown previously, 
the inflammasome effects are much more detrimental than beneficial for its homeo-
stasis. This detrimental effect has been observed in many neurological disorders 
where inflammasomes seem to provoke neurotoxicity, both directly or indirectly 
[2]. Among these disorders we have Alzheimer’s disease, bacterial meningitis, 
mouse’s equivalent multiple sclerosis, depression, etc. [2, 23, 25]. This evidence, 
built from clinical and experimental researches, is more often based on the obser-
vation of a rise in the expression of inflammasome NLRP3 in the CNS or in the 
peripheral blood or on the discovery of an anti-inflammasome activity of the drugs 
used in the treatment of these disorders. Table 2 summarizes for each neurological 
disorder the role played by inflammasome and inflammation in its pathogenesis. 
Another fact is that a unique neuron culture treatment with IL-1β does not produce 
deleterious effect; however, when the administration is prolonged for several days, 
it leads to neurotoxicity [34]. The negative impact of pro-inflammatory cytokines 
on the CNS is also seen on glial cells. Indeed, glial cells are the targets of pro-inflam-
matory cytokines and are activated by an inflammatory stimulus (PAMPs  
or DAMPs). This glial cell activation leads to the production of cytokines  
responsible of a local inflammatory response. Astrocytes activated by  
inflammation produce neurotrophins and growth factors like nerve growth  
factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell 
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line-derived neurotrophic factor (GDNF) [34]. These trophic factors have a neu-
roprotective effect. In contrast, microglial cell activation leads to the release of 
neurotoxic factors such as pro-inflammatory cytokines, chemokines, free radicals, 
nitric oxide, and metalloproteases [34]. For example, in the case of stroke, vascular 
interruption provokes an ischemia with neural lysis. This neural lysis is associated 
with a massive release of intracellular contents into the extracellular compartment, 
among which is glutamate. At this stage two neurotoxicity pathways are triggered: 
the excitotoxicity pathway by massive glutamate release and the inflammation path-
way by activation of microglial cells. Microglial cells are activated by the ischemic 
danger signal or through N-Methyl-D-aspartate (NMDA) receptors on their surface 
membrane that are sensible to glutamate [34]. This microglial cell activation leads 
to the production and release of pro-inflammatory cytokines and other molecules as 
specified previously. The consequences are neurotoxicity and in stroke an increase 
of the core ischemia at the expense of ischemic penumbra.
4.2 Metabolic syndrome as a cause of inflammation in neurotoxicity
Neurotoxicity as we aforementioned results from multiple biochemical processes 
including inflammation. Whether it is initiated and amplified at the level of the 
CNS or at the periphery, inflammation remains harmful to the CNS. As a matter of 
fact, when it comes to inflammation, there is a communication between the periph-
ery and the CNS [34]. Before addressing, at the end of this section, this connection 
between CNS and periphery, we would first of all want to present the metabolic 
syndrome as a cause of peripheral inflammation that could have an impact on the 
CNS. The metabolic syndrome is in fact a metabolic disorder characterized by a 
group of conditions that increase the risk of developing cardiovascular diseases and 
type 2 diabetes mellitus. Two mechanisms are suggested in an attempt to explain 
Neurological 
pathologies
Inflammasome 
actors
Experimental justifications References
Alzheimer’s 
disease
NLRP3, IL-1β Activation of inflammasome NLRP3 by 
β-amyloid protein and production IL-1β by 
microglial cell leading to neuro-inflammation 
and neurons death.
[23, 25]
Multiple 
sclerosis
NLRP3, ASC, 
IL-1β
Presence of SEP-like lesions in Muckle-Wells 
syndrome. Rise of gene’s expression and 
concentrations of caspase-1, IL-18 in peripheral 
mononuclear cells. Gene’s polymorphisms of 
caspase-1 is associated with SEP.
[26–28]
Amyotrophic 
lateral sclerosis
Caspase-1, IL-1β Activation of caspase-1 and IL-1β by a mutant 
of superoxide dismutase in microglial mouse cell 
provokes neuro-inflammation.
[29]
Parkinson’s 
disease
NLRP3, IL-1 Activation of inflammasome NLRP3 by 
α-synuclein protein. Neuro-degenerescence is 
accelerated by excess IL-1.
[30, 31]
Pneumococci 
meningitis
NLRP1, NLRP3, 
CARD8, ASC, 
IL-1β, IL-18
Gene’s polymorphisms of NLRP1 and CARD8 
and spinal fluid concentration of IL-1β and 
IL-18 are associated to clinical prognostic 
of meningitis. Low severity of meningitis in 
mouse’s models deficient to NLRP3and ASC or 
after inhibition of IL-1 or IL-18.
[32, 33]
Table 2. 
Implication of inflammasome in neurological pathologies (modified from [2]).
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the genesis of inflammation in metabolic syndrome. The first is a dysfunction of the 
organelles of adipocytes, observed in obesity; the second is adipose tissue hypoxia 
also observed in obesity [35]. The first mechanism suggests that hypertrophic 
adipose tissue found in obesity undergoes excessive lipolysis resulting in hyperlip-
idemia and an increase in circulating fatty acid levels. This increase in circulating 
levels of fatty acids, coupled with an abundance of carbohydrates, results in an 
increase in the oxidative activity of mitochondria that produce excess energy. As 
time goes by, this state results in a dysfunction of the mitochondria freeing a large 
quantity of electrons responsible for an increased production of reactive oxygen-
ated compounds. This oxidative stress can subsequently activate the innate immune 
system and thus cause inflammation. Furthermore, the excess of nutrients overruns 
the endoplasmic reticulum, resulting in a faulty plication of proteins which acti-
vates the response to faulty plication of proteins. This response stimulates the acti-
vation of three membranous proteins: PKR-like eukaryotic initiation factor 2-alpha 
kinase (PERK), inositol requiring enzyme-1 (IRE-1), and activating transcription 
factor-6 (AFT-6). PERK, IRE-1, and AFT-6 significantly enhance inflammation by 
activating the signaling pathway NF-kB [35].
Concerning the second mechanism, it is suggested that a localized hypoxia could 
initiate a dysregulation of adipokines in obesity. As a matter of fact, adipose tissue is 
mainly made up of adipocytes, but also preadipocytes, resident macrophages, fibro-
blasts, and endothelial cells. With the increase in adipose tissue observed in obesity, 
there is a need for a significant angiogenesis. The hypoxic signal present during 
this expansion results in the activation of transcription factors like the hypoxia-
inducible factors which are required in the activation of genes associated with 
angiogenesis, glucose metabolism, stress, and inflammation. Moreover, in vitro data 
reveal that human preadipocytes, when exposed to hypoxia, increase their expres-
sion of leptin and reduce their expression of the peroxisome proliferator-activated 
receptor gamma (PPARγ). Yet, agonists of the PPARγ stimulate insulinosensitivity 
and reduce inflammation. Furthermore, exposed to hypoxia, resident macrophages 
produce pro-inflammatory cytokines [35]. In type 2 diabetes, coupled with the 
mechanisms mentioned above, chronic hyperglycemia maintains a vicious circle. In 
fact, chronic hyperglycemia is responsible for an increase in glycation end products 
(AGEs) whose receptors belong to the family of PRRs. So, glycated plasma proteins, 
glycated lipids, or nucleic acids bind to AGE receptors present at the surface of 
macrophages and provoke a pro-inflammatory and pro-oxidative response [35].
Therefore, the metabolic syndrome induces a state of peripheral inflammation 
that becomes chronic because it is maintained by its causative process. This periph-
eral inflammation can directly affect the CNS through produced and circulating 
inflammatory mediators. These mediators penetrate the CNS via areas without a 
blood–brain barrier like the periventricular choroid plexuses following which they 
cause the aforementioned neurotoxic effects [34]. Furthermore, the blood–brain 
barrier is capable of transmitting an inflammatory message from the vascular endo-
thelium to the CNS via active mechanisms involving cyclooxygenases [34]. Through 
these mechanisms, an inflammation at the periphery, if it lasts long enough, can 
extend to the CNS and result in neurotoxicity and subsequent neurologic disorders.
4.3 Inflammation and neuroprotection
Actually, even if some anti-inflammatory strategies have proven their efficacy 
in animal models, none have demonstrated efficacy in humans in the prevention 
or treatment of neurological diseases associated with neurotoxicity. However, with 
conclusive experimental results on the use of anti-inflammatory drugs in neuro-
11
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research. In doing so, after bringing out the negative impact of inflammation on 
the central nervous system (CNS), it seems appropriate to present some strate-
gies explored or still to be explored in an attempt to inhibit neuro-inflammation 
and prevent or treat neurotoxicity associated with many neurological disorders. 
Glucocorticoid and general anesthesia products have stimulated a strong interest in 
neuroprotection in the cases of stroke on experimental animal models; this has not 
been demonstrated yet in humans [34]. Indeed, glucocorticoids have been found 
to be ineffective in stroke, head trauma, and meningeal hemorrhage [34]. And 
classic hypnotic agents like thiopental, midazolam, or propofol have peripheral 
immune-modulatory effects and are capable of inhibiting inflammatory response. 
They inhibit chemotaxis, adherence of neutrophils, phagocytosis, and liberation of 
free radicals and pro-inflammatory cytokines like IL-1β and TNFα in experimental 
mouse model; however, these activities have not been demonstrated in humans yet 
[34]. In general, having in mind previously described inflammation and inflamma-
tory neurotoxicity mechanisms, we can conclude that neuroprotection strategies 
based on modulation of inflammation have to maintain the beneficial roles of 
immunological defense and healing of inflammation while neutralizing its neuro-
toxic consequences. Thus, three anti-inflammatory strategies for neuroprotection 
axis can be developed: the modulation of the communication between peripheral 
inflammation and CNS, the modulation of interaction between pro-inflammatory 
cytokines and their intracerebral targets, and the modulation of inflammasome 
expression in CNS cells.
In relation to the first axis, namely, the modulation of the communication 
between peripheral inflammation and CNS and the COX inhibitors (nimesulide 
and indomethacin) has shown a neuroprotective activity in baby mice with brain 
lesions. This neuroprotective activity is made possible by inhibition of the com-
munication through the blood–brain barrier between activated peripheral inflam-
matory cells and the CNS [34]. With the same idea, the COX inhibitors have been 
presented as potentially beneficial in the treatment of major depression and other 
psychiatric disorders. Indeed, celecoxib has presented a beneficial effect in the 
treatment of major depression and schizophrenia especially in early stages [36]. 
Acetyl salicylic acid in particular seems to have both a preventive and therapeutic 
effect on schizophrenia [36]. Communication between peripheral inflammation 
and the CNS does not occur solely via the blood–brain barrier as it can also be done 
through the parasympathetic and sympathetic systems. Indeed, immune cells pres-
ent at their surfaces nicotinic receptors for acetylcholine and β-adrenergic receptors 
for catecholamine [34]. These receptors link immune cells to parasympathetic and 
sympathetic systems respectively. Thus, a pharmacologic vagal or noradrenergic 
stimulation could represent a potential target for neuroprotection. For this pur-
pose, vagal stimulation potentially passing through the modulation of lipocalin 
prostaglandin D2 synthase (L-PGDS) has shown in rat models with ischemic stroke 
a neuroprotective effect against ischemia reperfusion [37]. Also, a noradrenergic 
stimulation has shown, in Parkinson’s disease, a neuroprotective effect by inhibition 
of inflammation [38].
Concerning the modulation of interaction between pro-inflammatory cytokines 
and their intracerebral target strategy, specific receptor antagonist of IL-1 appears 
to be the most conclusive therapeutic approach. This antagonist is produced endog-
enously following brain injury, and its administration by systemic or intracerebral 
route leads to a reduction in the size of lesions in mouse models [34]. Furthermore, 
Veltkamp et al. report the use, via general route of anakinra, of an antagonist of 
IL-1 receptors in a clinical trial on a patient having stroke [39]. This clinical trial has 
shown a great reduction of national institute of health stroke scale (NIHSS), and 
it also shows more patient with modified Rankin score (mRS) of 0–1 in 3 months 
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[39]. Also based on this axis, sitagliptin, a molecule used in the treatment of type 2 
diabetes since the discovery of incretin effect, has shown a great anti-inflammatory 
capacity. This anti-inflammatory activity of sitagliptin is linked to the inhibition of 
synthesis of pro-inflammatory cytokine and a raise in anti-inflammatory cytokine 
synthesis [40]. This property has been exploited in the treatment of Alzheimer’s 
disease in mouse models, and the results were conclusive [40]. In humans, the 
administration of sitagliptin was associated with an amelioration of the mini-
mental state examination (MMSE) score used to evaluate dementia [40]. All these 
axes remain focused on more or less advanced stages of inflammation. For this 
reason, they carry the risk of possibly altering the beneficial effects of inflamma-
tion. Thus, to reduce this intrinsic risk, it seems necessary to develop more specific 
methods to modulate the inflammation. One method could be the inhibition of 
inflammasomes. However, because of the lack or incomplete knowledge on inflam-
masome structure and activation, this approach remains difficult. Nevertheless, the 
inhibition of NLRP3, the most studied inflammasome, has been subjected to several 
studies in psychiatric disorders [41]. A specific inhibitor of NLRP3 has been devel-
oped which lays the foundation for further exploration of this axis [42].
5. Conclusion
Neuroprotection is both a topical problem and a realistic dream for the 
researchers and clinicians. By this analysis, the immune system no more seems to 
only be a tool useful in the protection against endogenous and exogenous offend-
ers. As a matter of fact, its role could be understood as defense against all sorts 
of disorders, including infectious, metabolic, degenerative, etc. and even aging. 
Indeed, the role of the immune system and inflammation in disease-associated 
neurotoxicity is more and more highlighted in present literature. This evidence 
justifies the outbreak of an inflammatory approach to develop a neuroprotection 
strategy in the fight against neurotoxicity. All this evidence does not only provide 
hope for the future development of neuroprotective strategies, but also invite us 
to reflect on the possibility that failure of the immune system may be implicated 
as primary cause of any human pathology. In experimental research, this is in the 
process of being demonstrated for neurologic and psychiatric disorders. Even 
though clinically the results of the researches are not yet irrevocable, the inflamma-
tory pathway in neuroprotection remains a good approach in the fight against these 
main neurological ailments.
Acknowledgements
We wish to give thanks to Tchinda Fomekong Gérald, a resident of internal 
medicine, e-mail: fomekonggt@gmail.com, for all his support in the redaction of 
this chapter; Nana Rudy Arnaud, a resident of internal medicine, faculty of medi-
cine and biomedical sciences University of Yaoundé 1, e-mail: arnaud.nana@yahoo.
com; and Fombong T. Fombong, a resident of gynecology and obstetrics, faculty of 
medicine and biomedical sciences University of Yaoundé 1, e-mail: tfombongjnr@
gmail.com.
Conflict of interest
The authors declare that they have no competing interests.
13
Neuroprotection: The Way of Anti-Inflammatory Agents
DOI: http://dx.doi.org/10.5772/intechopen.90509
Author details
Patrice Mendel Nzogang* and Martial Boris Donkeng
Circle for Research, Development and Innovation (CIRDI), Yaoundé, Cameroon
*Address all correspondence to: nzogangmendel@gmail.com
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
14
Neuroprotection - New Approaches and Prospects
[1] Ganong WF, Barret KE, Barman SM, 
Boitano S, Brooks HL. Physiologie 
médicale. 3rd ed. Bruxelles: De Boerks; 
2012
[2] Jamilloux Y, Sève P, Henry T. Les 
inflammasomes et les maladies humaines. 
Revista Médica. 2014;35(11):730-741
[3] Brouns R, De Deyn PP. The 
complexity of neurobiological 
processes in acute ischemic stroke. 
Clinical Neurology and Neurosurgery. 
2009;111(6):483-495
[4] Ginsberg MD. Neuroprotection for 
ischemic stroke: Past, present and future. 
Neuropharmacology. 2008;55(3):363-389
[5] Onteniente B, Onteniente P, 
Bordet R. Médicaments neuroprotecteurs, 
neurogenèse, définitions, évaluations 
pré-cliniques, cliniques, guidelines… 
Communication à la: XXIèmes 
Rencontres de Pharmacologie Clinique; 
5-18 octobre 2005; Giens
[6] Burmester G, Pezzutto A. Atlas de 
poche d’immunologie: Bases, analyses 
biologiques, pathologies. Paris: 
Flammarion Médecine-Sciences; 2000
[7] Henrotin Y, Deby-Dupont G, 
Reginster JY. Les médiateurs biochimiques 
de l’inflammation. Revue Médicale de 
Liège. 2001;56(6):433-442
[8] Pickup J. Inflammation and activated 
innate immunity in the pathogenesis 
of type 2 diabetes. Diabetes Care. 
2004;27(3):813-823
[9] Lau P, Joly E. Le contexte 
immunologique très particulier du 
système nerveux central. Médecine/
sciences. 2001;17:395-401
[10] Perry VH, Andersson PB, Gordon S. 
Macrophages and inflammation in 
the central nervous system. Trends in 
Neurosciences. 1993;16:268-273
[11] Medzhitov R, Janeway CA Jr. 
Decoding the patterns of self and 
nonself by the innate immune system. 
Science. 2002;296(5566):298-300
[12] Matzinger P. The danger model: 
A renewed sense of self. Science. 
2002;296(5566):301-305
[13] Audinat E, Arnoux I. La microglie: 
des cellules immunitaires qui sculptent 
et contrôlent les synapses neuronales. 
Medical Science. 2014;30(2):153-159
[14] Hickey WF, Hsu BL, Kimura H. 
T-lymphocyte entry into the central 
nervous system. Journal of Neuroscience 
Research. 1991;28(2):254-260
[15] Flügel A, Schwaiger FW, 
Neumann H, Medana I, Willem M, 
Wekerle H, et al. Neuronal FasL induces 
cell death of encephalitogenic T 
lymphocytes. Brain Pathology. 
2000;10(3):353-364
[16] Griffith TS, Brunner T, Fletcher SM, 
Green DR, Ferguson TA. Fas ligand-
induced apoptosis as a mechanism 
of immune privilege. Science. 
1995;270(5239):1189-1192
[17] Joly E, Mucke L, Oldstone MB. Viral 
persistence in neurons explained 
by lack of major histocompatibility 
class I expression. Science. 
1991;253(5025):1283-1285
[18] Chen JJ, Sun Y, Nabel GJ. Regulation 
of the proinflammatory effects 
of Fas ligand (CD95L). Science. 
1998;282(5394):1714-1717
[19] Li XC, Wells AD, Strom TB, 
Turka LA. The role of T cell apoptosis 
in transplantation tolerance. 
Current Opinion in Immunology. 
2000;12(5):522-527
[20] Jamilloux Y, Henry T. Les 
inflammasomes Plates-formes de 
References
15
Neuroprotection: The Way of Anti-Inflammatory Agents
DOI: http://dx.doi.org/10.5772/intechopen.90509
l’immunité innée. Médecine/sciences. 
2013;29(11):975-984
[21] Ting JP, Lovering RC, 
Alnemri ES, Bertin J, Boss JM, 
Davis BK, et al. The NLR gene family: 
A standard nomenclature. Immunity. 
2008;28(3):285-287
[22] Poeck H, Bscheider M, Gross O, 
Finger K, Roth S, Rebsamen M, et al. 
Recognition of RNA virus by RIG-I 
results in activation of CARD9 and 
inflammasome signaling for interleukin 
1 beta production. Nature Immunology. 
2010;11(1):63-69
[23] Halle A, Hornung V, Petzold GC, 
Stewart CR, Monks BG, Reinheckel T, 
et al. The NALP3 inflammasome is 
involved in the innate immune response 
to amyloid-beta. Nature Immunology. 
2008;9(8):857-865
[24] Miao EA, Rajan JV, Aderem A. 
Caspase-1-induced pyroptotic cell 
death. Immunological Reviews. 
2011;243(1):206-214
[25] Nakanishi A, Kaneko N, Takeda H, 
Sawasaki T, Morikawa S, Zhou W, 
et al. Amyloid β directly interacts 
with NLRP3 to initiate inflammasome 
activation: Identification of an intrinsic 
NLRP3 ligand in a cell-free system. 
Inflammation and Regeneration. 
2018;38:27
[26] Compeyrot-Lacassagne S, 
Tran TA, Guillaume-Czitrom S, 
Marie I, Koné-Paut I. Brain multiple 
sclerosis-like lesions in a patient 
with Mückle–Wells syndrome. 
Rheumatology (Oxford, England). 
2009;48(12):1618-1619
[27] Jha S, Srivastava SY, Brickey WJ, 
Iocca H, Toews A, Morrison JP, et al. The 
inflammasome sensor, NLRP3, regulates 
CNS inflammation and demyelination 
via caspase-1 and interleukin-18. 
The Journal of Neuroscience. 
2010;30(47):15811-15820
[28] Ming X, Li W, Maeda Y, 
Blumberg B, Raval S, Cook SD, et al. 
Caspase-1 expression in multiple 
sclerosis plaques and cultured glial cells. 
Journal of the Neurological Sciences. 
2002;197(1-2):9-18
[29] Meissner F, Molawi K, Zychlinsky A. 
Mutant superoxide dismutase 1-induced 
IL-1beta accelerates ALS pathogenesis. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2010;107(29):13046-13050
[30] Codolo G, Plotegher N, 
Pozzobon T, Brucale M, 
Tessari I, Bubacco L, et al. Triggering 
of inflammasome by aggregated 
α-synuclein, an inflammatory response 
in synucleinopathies. PLoS One. 
2013;8(1):e55375
[31] Pott Godoy MC, Tarelli R, 
Ferrari CC, Sarchi MI, Pitossi FJ. Central 
and systemic IL-1 exacerbates 
neurodegeneration and motor 
symptoms in a model of Parkinson’s 
disease. Brain: A Journal of Neurology. 
2008;131(7):1880-1894
[32] Geldhoff M, Mook-Kanamori BB, 
Brouwer MC, Valls Seron M, Baas F, 
van der Ende A, et al. Genetic variation 
in inflammasome genes is associated 
with outcome in bacterial meningitis. 
Immunogenetics. 2013;65(1):9-16
[33] Hoegen T, Tremel N, Klein M, 
Angele B, Wagner H, Kirschning C, et al. 
The NLRP3 inflammasome contributes 
to brain injury in pneumococcal 
meningitis and is activated through 
ATP-dependent lysosomal cathepsin 
B release. Journal of Immunology. 
2011;187(10):5440-5451
[34] Degosa V, Chhora V, Gressensa P, 
Mantza J. Neuroprotectrive strategies 
and acute neuro-inflammation. 
Réanimation. 2009;18:556-565
[35] Calle M, Fernandez M. 
Inflammation and type 2 diabetes. 
Neuroprotection - New Approaches and Prospects
16
Diabetes and Metabolism. 
2012;38(3):183-191
[36] Müller N. COX-2 inhibitors, aspirin, 
and other potential anti-inflammatory 
treatments for psychiatric disorders. 
Psychiatry. 2019;10:375
[37] Zhang L, Ma J, Jin X, Jia G, Jiang Y, 
Li C. L-PGDS mediates vagus nerve 
stimulation-induced neuroprotection 
in a rat model of ischemic stroke 
by suppressing the apoptotic 
response. Neurochemical Research. 
2017;42(2):644-655
[38] O’Neill E, Harkin A. Targeting 
the noradrenergic system for anti-
inflammatory and neuroprotective 
effects: Implications for Parkinson’s 
disease. Neural Regeneration Research. 
2018;13(8):1332-1337
[39] Veltkamp R, Gill D. Clinical trials of 
immunomodulation in ischemic stroke. 
Neurotherapeutics. 2016;13(4):791-800
[40] WiciNski M, Wódkiewicz E, 
Słupski M, Walczak M, Socha M, 
Malinowski B, et al. Neuroprotective 
activity of sitagliptin via reduction 
of neuroinflammation beyond the 
incretin effect: Focus on Alzheimer’s 
disease. BioMed Research International. 
2018;2018:9
[41] Herman FJ, Pasinetti GM. Principles 
of inflammasome priming and 
inhibition: Implications for psychiatric 
disorders. Brain, Behavior, and 
Immunity. 2018;73:66-84
[42] Ludwig-Portugall I, 
Bartok E, Dhana E, Evers BD, 
Primiano MJ, Hall JP, et al. An NLRP3-
specific inflammasome inhibitor 
attenuates crystal-induced kidney 
fibrosis in mice. Kidney International. 
2016;90(3):525-539
